SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

IGREJA, Ana Carolina de Souza Machado; MESQUITA, Kleyton de Carvalho; COWPER, Shawn Edwin  and  COSTA, Izelda Maria Carvalho. Nephrogenic systemic fibrosis: concepts and perspectives. An. Bras. Dermatol. [online]. 2012, vol.87, n.4, pp. 597-607. ISSN 0365-0596.  http://dx.doi.org/10.1590/S0365-05962012000400013.

    1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1. [ Links ]

    2. Basak P, Jesmajian S. Nephrogenic Systemic Fibrosis: Current Concepts. Indian J Dermatol. 2011;56:59-64. [ Links ]

    3. Cordova KB, Oberg TJ, Malik M, Robinson-Bostom L. Dermatologic conditions seen in end-stage renal disease. Semin Dial. 2009;22:45-55. [ Links ]

    4. Mundim JS, Lorena SC, Abensur H, Elias RM, Moysés RMA, Castro MCM, Romão Júnior JE. Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure. Rev Assoc Med Bras. 2009;55:220-5. [ Links ]

    5. Lee CU, Wood CM, Hesley GK, Leung N, Bridges MD, Lund JT, et al. Large sample of nephrogenic systemic fibrosis cases from a single institution. Arch Dermatol. 2009;145:1095-102. [ Links ]

    6. Newton BB, Jimenez SA. Mechanism of NSF: new evidence challenging the prevailing theory. J Magn Reson Imaging. 2009;30:1277-1283. [ Links ]

    7. Girardi M, Kay J, Elston DM, LeBoit PE, Abu-Alfa A, Cowper SE. Nephrogenic Systemic Fibrosis: Clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65:1095-1106.e7. [ Links ]

    8. Introcaso CE, Hivnor C, Cowper S, Werth VP. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of literature. Int J Dermatol. 2007;46:447-452. [ Links ]

    9. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial. 2008;21:123-8. [ Links ]

    10. icnsfr.org.[homepage]. Nephrogenic Fibrosing Dermopathy [ICNSFR Website]. 2001-2009. [cited 2011 May 28]. Available from: http://www.icnsfr.org. [ Links ]

    11. Braverman IM, Cowper SE. Nephrogenic systemic fibrosis. F1000 Med Rep. 2010;2:84 -8. [ Links ]

    12. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol. 2009;53:1621-8. [ Links ]

    13. DiCarlo JB, Gupta EA, Solomon AR. A pediatric case of nephrogenic fibrosing dermopathy: Improvement after combination therapy. J Am Acad Dermatol. 2006;54:914-6. [ Links ]

    14. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264-7. [ Links ]

    15. Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep. 2007;56:137-141. [ Links ]

    16. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-8. [ Links ]

    17. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174- 8. [ Links ]

    18. Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress? Int J Dermatol. 2011;50:659-66. [ Links ]

    19. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol. 2007;18:2636-43. [ Links ]

    20. Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol. 1999;34:443-55. [ Links ]

    21. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: A cause for concern. Semin Dial. 2007;20:179-85. [ Links ]

    22. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491-502. [ Links ]

    23. Runge VM. Safety of magnetic resonance contrast media. Top Magn Reson Imaging. 2001;12:309-14. [ Links ]

    24. Bruder O, Schneider S, Nothnagel D, Pilz G, Lombardi M, Sinha A, et al. Acute Adverse Reactions to Gadolinium-Based Contrast Agents in CMR. JACC Cardiovasc Imaging. 2011;4:1171 - 6. [ Links ]

    25. Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens. 2009;18:519-25. [ Links ]

    26. ema.europa.eu [homepage]. London: Questions and answers on the review of gadolinium-containing contrast agents. 2010. [cited 2011 Dec 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500015635.pdf. [ Links ]

    27. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Wilich H, Siegmund F, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164-73. [ Links ]

    28. Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. Stability of gadoliniumbased magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-28. [ Links ]

    29. Goddard DS, Magee CC, Lazar AJF, Miller DM. Nephrogenic fibrosing dermopathy with recurrence after allograft failure. J Am Acad Dermatol. 2007;56:S109-111. [ Links ]

    30. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;25:358. [ Links ]

    31. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27-30. [ Links ]

    32. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21- 6. [ Links ]

    33. Idee JM, Port M, Raynal I, Schaefer M, Greneur SL, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-76. [ Links ]

    34. Ballen K. Targeting the stem cell niche: squeezing blood from bones. Bone Marrow Transplant. 2007;39:655-60. [ Links ]

    35. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003; 102:1340-6. [ Links ]

    36. Fazekas Z, Davies J, Phelps R, Lebwohl M. A case of nephrogenic fibrosing dermopathy in a liver transplant recipient. J Am Acad Dermatol. 2007;56:AB58. [ Links ]

    37. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep. 2006;8:151-7. [ Links ]

    38. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garret AL, Garret RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-57. [ Links ]

    39. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamideassociated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586-92. [ Links ]

    40. Cowper SE. Nephrogenic systemic fibrosis: an overview. J Am Coll Radiol. 2008;5:23- 8. [ Links ]

    41. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191-9. [ Links ]

    42. Streams BN, Liu V, Liégeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003;48:42-7. [ Links ]

    43. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int. 2008;73:1413- 8. [ Links ]

    44. High WA, Eng M, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:710-2. [ Links ]

    45. High WA, Ranville JF, Brown M, Punshon T, Lanzirotti A, Jackson BP. Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. J Am Acad Dermatol. 2010;62:38-44. [ Links ]

    46. Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and endstage renal disease. Clin J Am Soc Nephrol. 2008;3:968-75. [ Links ]

    47. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: Relationship to gadolinium and response to photopheresis. Arch Dermatol. 2007;143:1025-30. [ Links ]

    48. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadoliniumbased contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258-63. [ Links ]

    49. Elmholdt TR, Pedersen M, Jørgensen B, Ramsing M, Olesen AB. Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. Acta Derm Venereol. 2011;91:478-9. [ Links ]

    50. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543-8. [ Links ]

    51. Chandran S, Petersen J, Jacobs C, Florentino D, Doeden K, Lafayette RA. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis. 2009;53:129-32. [ Links ]

    52. Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant. 2011;26:1099-101. [ Links ]

    53. Mayr M, Burkhalter F, Bongartz G. Nephrogenic Systemic Fibrosis: Clinical Spectrum of Disease. J Magn Reson Imaging. 2009;30:1289-97. [ Links ]

    54. Saxena SK, Sharma M, Patel M, Oreopoulos D. Nephrogenic systemic fibrosis: an emerging entity. Int Urol Nephrol. 2008;40:715-24. [ Links ]